Conference Coverage

International expert group agrees on redefining psoriasis severity

Publish date: December 1, 2020

 

FROM MEDSCAPELIVE LAS VEGAS DERMATOLOGY SEMINAR

MedscapeLive and this news organization are owned by the same parent company.

bjancin@mdedge.com

Pages

Recommended Reading

FDA approves ixekizumab for pediatric plaque psoriasis
Journal of Clinical Outcomes Management
‘We’re in great distress here,’ infusion center CMO says
Journal of Clinical Outcomes Management
Financial incentives affect the adoption of biosimilars
Journal of Clinical Outcomes Management
Latest data on COVID-19 patients with rheumatic diseases revealed in registry
Journal of Clinical Outcomes Management
Case series suggests biologics, JAK inhibitors safe during pandemic
Journal of Clinical Outcomes Management
Doctors hesitated to embrace biosimilar infliximab in first 2 years
Journal of Clinical Outcomes Management
New psoriasis guidelines focus on topical and alternative treatments, and severity measures
Journal of Clinical Outcomes Management
COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate
Journal of Clinical Outcomes Management
Shingrix effective in older adults with preexisting immune-mediated disorders
Journal of Clinical Outcomes Management
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
Journal of Clinical Outcomes Management